Sanofi-Aventis: favorable opinion on the Multaq
Good news for Sanofi-Aventis. The pharmaceutical giant has obtained a favorable opinion of the Commission on Transparency Multaq medical interest, reveals the Tribune Wednesday. This drug for cardiac arrhythmias in place of amiodarone which generates significant side effects, had been criticized by the French authorities as a renowned American Institute cardialogie.
The Transparency Committee eventually concluded that "the Multaq does not improve the medical service rendered in relation to amiodarone (…) but represents a useful supplementary therapy. Experts believe that the "medical service rendered" is "important" when they had considered "moderate" in the first review in March.
This advisory opinion warrants a refund of 65% of Multaq, but it does not fix the selling price. This will be negotiated with the Ministry of Health.The daily La Tribune said that the opinion of the Commission should result in a price lower than the products already marketed. The laboratory should therefore support price negotiations with a strong argument: the reduction of hospitalizations and deaths due to medication.
900 million euros turnover in 2013 horzon
While numerous patents expire Group, Sanofi-Aventis place great hope in the Multaq: Analysts expect 900 million euros turnover in 2013, according to business daily.
The new drug is already marketed in several countries like Germany, the United States, the United Kingdom, Denmark, Norway, Ireland, Switzerland or Canada. A spokesman for the pharmaceutical group has confirmed a target marketing Multaq in France by the end of the year.